Completed PHASE1 INTERVENTIONAL 1-arm NCT02151760

Study of 18F-DCFPyL, a Second Generation Low-molecular Weight PSMA-based PET Radiotracer, in Patients With Prostate Cancer

Sponsor: National Cancer Institute (NCI)

Interventions 18F-DCFPyL

Updated 9 times since 2017 Last updated: May 5, 2020 Started: May 31, 2014 Primary completion: Apr 30, 2020 Completion: Apr 30, 2020

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Metastatic Prostate Cancer, this trial is completed. The trial is conducted by National Cancer Institute (NCI) and has accumulated 9 data snapshots since 2014. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

9 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2020 — Jan 2021 [monthly]

Completed PHASE1

Status: Active Not Recruiting → Completed
Jun 2019 — Jun 2020 [monthly]

Active Not Recruiting PHASE1

▶ Show 4 earlier versions

Jun 2018 — Jun 2019 [monthly]

Active Not Recruiting PHASE1
Jun 2017 — Jun 2018 [monthly]

Active Not Recruiting PHASE1

Status: Recruiting → Active Not Recruiting
Feb 2017 — Jun 2017 [monthly]

Recruiting PHASE1
Jan 2017 — Feb 2017 [monthly]

Recruiting PHASE1

First recorded

May 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Cancer Institute (NCI)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Data source: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Baltimore, United States